期刊文献+

托法替布及其光学异构体的NP-HPLC法分离与测定

Separation and Determination of Tofacitinib and Its Optical Isomers by NP-HPLC
原文传递
导出
摘要 建立了正相高效液相色谱法分离托法替布及其光学异构体,并定量测定其对映异构体和非对映异构体。采用Chiralpak AS-H手性柱,以正己烷∶乙醇∶甲醇∶乙醇胺(70∶20∶10∶0.2)为流动相,检测波长290 nm。托法替布及其光学异构体均分离完全。3R,4S-型、3S,4R-型非对映异构体和3S,4S-型对映异构体分别在0.6~12、0.6~12和0.5~10μg/ml范围内线性关系良好;平均回收率分别为100.8%、98.8%和98.6%,RSD分别为1.21%、1.34%和1.61%。 An NP-HPLC method was established for the chiral separation of tofacitinib and its optical isomers, as well as the determination of the enantiomer and diastereoisomers. A Chiralpak AS-H column was used, with the mobile phase of hexane : ethanol : methanol :2-aminoethanol (70 :20 :10 :0.2) at the detection wavelength of 290 nm. Tofacitinib and its optical isomers could be separated completely. Their were linear for the (3R,4S)- and (3S,4R)- diastereoisomers and (3S,4S) - enantiomer in the ranges of 0.6-12, 0.6-2 and 0.5-10 μg/ml, respectively. The average recoveries of diastereoisomers and enantiomer were 100.8 %, 98.8 % and 98.6 %, with RSDs of 1.21%, 1.34 % and 1.61%, respectively.
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2016年第5期600-603,共4页 Chinese Journal of Pharmaceuticals
关键词 枸橼酸托法替布 对映异构体 非对映异构体 手性拆分 高效液相色谱 测定 tofacitinib citrate enantiomer diastereoisomer chiral separation HPLC determination
  • 相关文献

参考文献7

  • 1张建忠.2012年11月FDA批准新药概况[J].上海医药,2013,34(1):61-61. 被引量:5
  • 2郭宗儒.化学生物学与药物化学研发托伐替尼[J].药学学报,2014,49(2):282-284. 被引量:4
  • 3王燕娇,刘永进,郭文敏,白培锋,何影.枸橼酸托法替布中的四种光学异构体的HPLC法测定[J].中国医药工业杂志,2015,46(9):1007-1009. 被引量:1
  • 4Kasat RB, Wang NH, Franses EI. Experimental probing and modeling of key sorbent-solute interactions of norephedrine enantiomers with polysaccharide-based chiral stationary phases [J]. J Chromatogr A, 2008, 1190 (1-2) : 110-119.
  • 5Stringham RW, Ye YK. Chiral separation of amines by high- performance liquid chromatography using polysaccharide stationary phases and acidic additives [J]. J Chromatogr A, 2006, 1101 (1-2) : 86-93.
  • 6Cai WL, Colony JL, Frost H, et al. Investigation of practical routes for the kilogram-scale production of cis-3- methylamino-4-methylpiperidines [J]. Org Process Res Dev, 2005, 9: 51-56.
  • 7Patil YS, Bonde NL, Kekan AS, et al. An improved and efficient process for the preparation of tofacitinib citrate [J]. Org Process Res Dev, 2014, 18 (12) : 1714-1720.

二级参考文献5

  • 1惠伯棣,李京,裴凌鹏.应用C_(30)-HPLC-PDA分离与鉴定食品中全反式叶黄素和玉米黄素[J].食品科学,2006,27(9):151-154. 被引量:13
  • 2Kawalec P, Mikrut A, Wi~niewska N, et al. The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis [J]. Clin Rheumatol, 2013, 32 (10) : 1415-1424.
  • 3Kumar S, Govind R, Nagaraju Ch.V.S, et al. Stability indicating HPLC method for the quantification of tofacitinib citrate and its related substances [J]. Der Pharma Chemica, 2014, 6(2): 11-19.
  • 4Moros EE, Darnoko D, Cheryan M, et al. Analysis of xanthophylls in corn by HPLC [J]. JAgric Food Chem, 2002, 50 (21) : 5787-5790.
  • 5黄晓龙.美国FDA关于开发立体异构体新药的政策简介[J].中国新药杂志,2000,9(9):650-652. 被引量:18

共引文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部